Home
This site is intended for healthcare professionals
Sign upLog in

Key Clinical Summary: Evolving Approaches to First-Line Therapy and Maintenance for HER2+ Metastatic Breast Cancer

This is a summary of the sessions by Seth Wander, MD which you can find here

The management of first-line HER2-positive metastatic breast cancer (MBC) is entering a period of rapid evolution. While the CLEOPATRA regimen established taxane plus trastuzumab and pertuzumab (THP) followed by HP maintenance as the long-standing standard of care, several landmark studies presented at ASCO 2026 have introduced new options for induction and maintenance therapy. These data support a more individualized treatment approach guided by tumour biology, hormone receptor status, depth of response and toxicity considerations.

Based on data highlighted at the ASCO 2026 Annual Meeting, clinical practice must now adapt to new regimens that optimize induction therapy, personalize maintenance based on hormone receptor (HR) status, and proactively manage toxicities.

ASCO 2026 Highlights & Practice-Changing Data

1. DESTINY-Breast09: T-DXd + Pertuzumab in 1L HER2+ MBC

  • Efficacy: Fam-trastuzumab deruxtecan-nxki (T-DXd) combined with pertuzumab demonstrated a substantial progression-free survival (PFS) benefit over standard THP (median PFS of 40.7 months vs. 26.9 months).
  • Clinical implication: Patients receiving T-DXd plus pertuzumab may continue to deepen their response over many months. An early partial response should not automatically prompt de-escalation to a maintenance strategy, as median time to best response among patients achieving complete or deep partial responses was approximately 8–10 months. Continued therapy in clinically stable patients may therefore maximise treatment benefit.
  • Status: These findings supported FDA approval of T-DXd plus pertuzumab as a first-line treatment option for unresectable or metastatic HER2-positive breast cancer.

2. PATINA: Optimizing Maintenance in HR+/HER2+ MBC

  • Efficacy: For patients with HR+/HER2+ disease who complete induction chemotherapy without progression, adding the CDK4/6 inhibitor palbociclib to anti-HER2 therapy and endocrine therapy (ET) significantly improved outcomes. Median PFS increased from 29.1 months to 44.3 months.
  • Clinical Pearl for Practice: Maintenance decisions for HR-positive disease should now be guided by hormone receptor status rather than simply discontinuing chemotherapy. Following induction, maintenance therapy could incorporate endocrine therapy together with anti-HER2 therapy and CDK4/6 inhibition in appropriate patients.
  • Status: The FDA approved palbociclib combined with trastuzumab (with or without pertuzumab) and endocrine therapy for maintenance treatment in this specific population.

3. HER2CLIMB-05: Tucatinib Maintenance Post-THP Induction

  • Efficacy: In patients receiving tucatinib plus HP maintenance after completing THP induction, median PFS improved from 16.3 months (with placebo + HP) to 24.9 months.
  • Clinical Pearl for Practice: Tucatinib maintenance represents an additional treatment option following THP induction, with the greatest progression-free survival benefit observed in patients with HR-negative disease. Careful patient selection together with proactive toxicity monitoring will be essential to maximise benefit.

Optimizing Long-Term Outcomes & Toxicity Management

Intensifying maintenance therapies introduces new adverse-event profiles that require vigilant monitoring to ensure treatment continuity.

  • Clinical considerations: Successful implementation of these intensified maintenance strategies requires proactive toxicity management. Tucatinib-containing regimens require careful monitoring for diarrhoea and ALT/AST elevations, routine CBCs are recommended for palbociclib, while T-DXd plus pertuzumab requires ongoing surveillance for treatment-related adverse events to maintain long-term treatment and quality of life.

Summary of Clinical Practice

Recent evidence suggests that first-line management of HER2-positive metastatic breast cancer is becoming increasingly personalised rather than following a single treatment pathway. Clinical decision-making should now consider:

  • Considering T-DXd plus pertuzumab as a new first-line treatment option for appropriate patients.
  • Incorporating endocrine therapy and palbociclib into maintenance treatment for patients with HR-positive disease following induction therapy.
  • Considering tucatinib plus trastuzumab/pertuzumab maintenance for selected patients, particularly those with HR-negative disease.
  • Proactively managing treatment-related toxicities to optimise long-term treatment adherence and patient outcomes.

Overall, these studies represent a shift from a single standard maintenance approach towards biology-driven, individualised treatment sequencing, where hormone receptor status, response depth and toxicity profile increasingly guide first-line therapeutic decisions.